Skip to content
Compare prices

Independent UK medicine guidance

Mounjaro and diabetic eye changes: retinopathy, blurred vision and what to tell your doctor

This page is for people with type 2 diabetes. The Mounjaro (tirzepatide) leaflet asks you to talk to your doctor before starting if you have a problem with your eyes such as diabetic retinopathy or macular oedema. The reason is not that the medicine harms the eye directly; it is that a rapid improvement in blood glucose, which tirzepatide can produce, has been linked with a temporary worsening of existing diabetic eye disease. If you do not have diabetes, this warning does not apply to you, although blurred vision from dehydration or low blood sugar can happen to anyone and is covered too.

Written by: Nick Johnson, Independent Prescription Pricing Analyst, Medstack Ltd  |  Published: 6 September 2026  |  Checked: 6 September 2026  |  Next scheduled review: 6 December 2026

Key facts

  • The leaflet lists diabetic retinopathy and macular oedema among the things to tell your doctor about before using Mounjaro.[1]
  • The SmPC says tirzepatide has not been studied in people with non-proliferative retinopathy requiring acute therapy, proliferative retinopathy or diabetic macular oedema, and should be used with caution in them, with appropriate monitoring.[2] It does not claim the medicine damages the eye.
  • This is a known effect of good glucose control arriving quickly, seen with insulin and other diabetes medicines, not something specific to tirzepatide.
  • Everyone with diabetes in the UK is invited to NHS diabetic eye screening; keep every appointment, and tell the screening service you have started Mounjaro.[3]
  • Red flag: sudden vision loss, a curtain or shadow across your vision, or a sudden shower of floaters needs same-day eye assessment via 111 or an eye casualty.

Why the warning exists

Diabetic retinopathy is damage to the small blood vessels at the back of the eye caused by years of high glucose. When glucose comes down quickly, the retina’s blood supply changes faster than the vessels can adapt, and in some people existing retinopathy gets worse for a period before the long-term benefit of better control takes over. This “early worsening” was first described with intensive insulin treatment and has since been seen with other glucose-lowering treatment.

The UK product information for tirzepatide does not make that claim directly. What it says is narrower and worth quoting accurately: tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy or diabetic macular oedema, and should be used with caution in these patients with appropriate monitoring.[2] In other words, the caution exists because those patients were excluded from the trials, not because harm has been demonstrated. Since tirzepatide can lower HbA1c substantially within months, the early-worsening pattern is the reason clinicians take that caution seriously.

The concern is concentrated in people who already have retinopathy, especially more advanced disease, and in those whose glucose was very high beforehand. If your diabetes was well controlled and your last screening was clear, the warning is a reason for monitoring, not alarm.

If you have type 2 diabetes: before and after starting

  1. Tell the prescriber about your eyes. Whether you have ever been told you have retinopathy or macular oedema, when your last screening was, and what it showed. An online questionnaire may not ask; answer anyway.
  2. Tell your GP or diabetes team you are on Mounjaro, including if you obtained it privately. Our guide explains what your pharmacy has told them.
  3. Keep your screening appointment, and ask whether it should be brought forward. The NHS screening programme is the monitoring the SmPC is talking about.[3]
  4. Review your other diabetes medicines with your prescriber. Insulin and sulphonylureas may need adjusting to avoid low blood sugar, which can also blur vision.[1]
  5. Report any change in vision promptly, rather than waiting for the next annual check.

Blurred vision that is not retinopathy

Two other things blur vision on Mounjaro and both are temporary.

Changing glucose levels alter the shape of the lens for a few weeks while the body adjusts, in anyone whose glucose has moved a lot. Opticians see this often in newly treated diabetes and usually advise waiting for glucose to stabilise before changing a glasses prescription.

Dehydration and low blood pressure, both common in the early weeks, can cause light-headedness and momentary blurring, especially on standing. See dizziness and low blood pressure. Low blood sugar is a cause if you take insulin or a sulphonylurea; see low blood sugar on Mounjaro.

When to get help

Same day, via NHS 111 or an eye casualty department: sudden loss of vision in one or both eyes, a dark curtain or shadow moving across your vision, a sudden increase in floaters or flashes, or eye pain with vision change. These are emergencies whatever medicine you take.

Within days, via your GP, optician or diabetes team: gradual blurring that lasts more than a few weeks, distortion of straight lines, difficulty reading that is new, or any vision change if you have known retinopathy. Tell them you are on Mounjaro and when you started.

Common questions

Does Mounjaro damage your eyes?

Not directly, and the UK product information does not say it does. It asks for caution and monitoring in people with existing diabetic retinopathy or macular oedema, because those patients were not studied. Separately, a rapid improvement in glucose from any treatment can temporarily worsen existing retinopathy. People without diabetes are not affected by this warning.

Why is my vision blurry on Mounjaro?

Shifting glucose levels change the lens for a few weeks; dehydration and low blood pressure cause brief blurring on standing; and low blood sugar is a cause for people on insulin or sulphonylureas. Sudden or persistent vision change needs assessment.

Can I take Mounjaro if I have diabetic retinopathy?

The product information asks for monitoring rather than ruling it out. It is a decision for your prescriber with your diabetes team and eye screening service, made with your eye history in front of them.

Should I change my glasses prescription on Mounjaro?

Opticians usually advise waiting until glucose has been stable for a couple of months, because the lens can change shape while glucose is moving. Tell your optician you are on Mounjaro.

Related guides

About this page. Monj is an independent information and price comparison service run by Medstack Ltd. It is not a pharmacy and does not prescribe, dispense or sell medicines. This page provides general information, not diagnosis or individual medical advice, and it does not replace NHS diabetic eye screening. It has not been clinically reviewed; a named clinical reviewer will be added when one has approved it. Read our editorial and review policy and independence statement.

References

  1. Eli Lilly. Mounjaro KwikPen: Package leaflet, information for the patient (UK), revised August 2026, section 2. electronic medicines compendium. medicines.org.uk/emc/product/15481/pil. Accessed 6 September 2026.
  2. Eli Lilly. Mounjaro KwikPen: Summary of Product Characteristics (UK), section 4.4. electronic medicines compendium. medicines.org.uk/emc/product/15481/smpc. Accessed 6 September 2026.
  3. NHS. Diabetic eye screening. nhs.uk/conditions/diabetic-eye-screening. Accessed 6 September 2026.
  4. NHS. Diabetic retinopathy. nhs.uk/conditions/diabetic-retinopathy. Accessed 6 September 2026.

Explore other side effects

Tap a point on the body to jump to that symptom, or choose from the full list below. The pink marker shows where you are now.

Open the full interactive symptom map

© 2026 Medstack Ltd. Written and published by Monj (monj.co.uk). You are welcome to link to this page or quote a short extract with a credit and a link. Republishing the text, page structure, safety-routing design or price data, in whole or in part, including to train or ground an automated system, is not permitted without written permission. See our independence statement and editorial and review policy.

Monj is an independent price comparison index operated by Medstack Ltd. We are not a pharmacy and we do not sell, prescribe, supply or dispense medicines. Listings are ranked strictly by the lowest total patient price, with alphabetical order used to break ties. No pharmacy can pay for placement, ranking or badges. Some outbound links earn a referral commission, and this never affects position or inclusion. Read the full independence statement.